1 Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a progressive respiratory disease characterized by persistent airflow limitation and chronic inflammation of the airways and lungs. It is a major global health issue, affecting millions of people worldwide and significantly contributing to morbidity and mortality rates. COPD is primarily caused by long-term exposure to irritants, such as tobacco smoke, air pollution, and occupational dust. Smoking remains the most significant risk factor. The disease's prevalence continues to rise, and it is projected to become the third leading cause of death globally (Cagle et al., 2023).

COPD is characterized by a combination of small airway disease and parenchymal destruction, leading to airflow limitation and impaired gas exchange. Key components of the disease pathophysiology include chronic inflammation, oxidative stress, and an imbalance between protease and antiprotease activity, which contribute to the degradation of lung tissues. The disease's progressive nature often leads to frequent exacerbations, hospitalizations, and worsening of symptoms over time (Briganti and D'Ovidio, 2017). Long-term management is critical in COPD due to its progressive nature. Pharmacological treatments, such as bronchodilators and inhaled corticosteroids, help control symptoms and reduce exacerbations. Non-pharmacological strategies, like pulmonary rehabilitation, lifestyle modifications, and smoking cessation, are essential in slowing disease progression and improving quality of life (Harrison and Kim, 2019). Long-term management, including appropriate pharmacotherapy and lifestyle interventions, has been shown to improve lung function, reduce exacerbation rates, and enhance overall survival rates (Güell et al., 2017).

The primary objective of this case review is to analyze classic cases in long-term management of COPD, with a focus on the efficacy of different therapeutic strategies in managing the disease over extended periods. By examining these cases, the study aims to highlight the importance of personalized management approaches, including pharmacological and non-pharmacological interventions, to improve patient outcomes and quality of life. This review provides insights into best practices and the significance of long-term management in reducing exacerbations, hospitalizations, and mortality. Understanding the variability in patient responses to treatments is essential for tailoring individualized therapeutic approaches. The findings will contribute to the ongoing development of guidelines and strategies aimed at optimizing COPD management, particularly in patients with severe or end-stage disease.

2 Long-term Management Strategies for COPD

2.1 Classic cases of pharmacological treatments

Pharmacological management is a cornerstone in the long-term treatment of COPD, particularly in patients with moderate to severe disease. Long-acting bronchodilators, such as long-acting muscarinic antagonists (LAMAs) and long-acting β2-agonists (LABAs), form the foundation of pharmacotherapy. Dual bronchodilation, combining LAMA and LABA, is widely used in COPD patients to improve lung function, alleviate symptoms, and reduce exacerbation frequency. In classic case studies, patients who experience frequent exacerbations despite dual therapy may benefit from the addition of inhaled corticosteroids (ICS) to form triple therapy. For patients with higher eosinophil counts, adding ICS to the regimen has been shown to reduce exacerbation rates, especially in cases of asthma-COPD overlap (Harrison and Kim, 2019).

Furthermore, specific phenotypes of COPD, such as those involving chronic bronchitis, may respond better to therapies that include phosphodiesterase-4 inhibitors (e.g., roflumilast) or macrolide antibiotics. These strategies aim to reduce inflammation and manage bacterial load in the airways. Recent evidence suggests that personalized pharmacotherapy, based on patient characteristics such as the frequency of exacerbations and eosinophil levels, is critical in optimizing outcomes. These classic cases illustrate how tailoring pharmacological approaches to individual needs can greatly enhance long-term disease control and quality of life for COPD patients (Miravitlles et al., 2016).

2.2 Classic cases of non-pharmacological interventions

Non-pharmacological interventions play a critical role in COPD management, particularly in improving patients' functional status and overall quality of life. Pulmonary rehabilitation, which integrates physical exercise, nutritional advice, and psychological support, has been shown to significantly improve exercise capacity and reduce the frequency of hospitalizations in severe COPD patients. Case studies demonstrate that patients enrolled in long-term rehabilitation programs experience better control over symptoms and fewer exacerbations. For example, one study found that pulmonary rehabilitation maintenance programs over a three-year period helped maintain improvements in lung function and quality of life, even reducing the rate of exacerbations (Güell et al., 2017).

Oxygen therapy is another critical intervention for patients with chronic hypoxemia. Long-term oxygen therapy (LTOT) not only improves survival rates but also enhances daily functioning and reduces complications related to oxygen deficiency. Classic cases have shown that patients who adhere to LTOT for more than 15 hours per day experience reduced mortality rates and improved quality of life. Additionally, the advent of telerehabilitation has opened up new avenues for long-term management, enabling remote monitoring and personalized exercise programs. This approach has proven effective in sustaining the benefits of rehabilitation over extended periods (Zanaboni et al., 2017).

2.3 Case studies on personalized treatment plans and stable COPD management

Stable COPD management often requires a personalized approach to address the variability in patient responses to treatment. In several case studies, individualized treatment plans have been shown to improve outcomes in COPD patients. For instance, patients with frequent exacerbations and high eosinophil levels respond well to ICS-based therapies, while others benefit more from dual bronchodilator therapy. In some cases, long-term use of macrolide antibiotics or phosphodiesterase-4 inhibitors has been used to manage patients with chronic bronchitis or frequent bacterial infections. Personalized treatment plans help to stabilize lung function and reduce exacerbation frequency, improving the overall quality of life for patients (Vogelmeier et al., 2020).

Furthermore, regular monitoring and reassessment are essential components of stable COPD management. In classic cases, patients who received continuous follow-up care, including lung function tests and symptom monitoring, had better disease control. Adjusting medications based on disease progression and patient-reported symptoms helped in maintaining stability. Multidisciplinary approaches, incorporating respiratory therapists, nutritionists, and mental health support, further enhance the effectiveness of these personalized plans (Scalone et al., 2018).

2.4 Management and prevention strategies for acute exacerbations

Acute exacerbations are a hallmark of COPD progression and often lead to hospitalizations, increased healthcare costs, and deteriorating health. Management strategies for acute exacerbations typically involve prompt pharmacological interventions, including bronchodilators, systemic corticosteroids, and antibiotics when bacterial infections are suspected. For patients with severe respiratory failure, non-invasive ventilation (NIV) has proven to be an effective intervention in preventing intubation and improving recovery outcomes (Crisafulli et al., 2018).

Preventive strategies for reducing the frequency and severity of exacerbations focus on optimizing long-term maintenance therapy. Patients at high risk for exacerbations often benefit from triple therapy (ICS/LABA/LAMA) or the use of phosphodiesterase-4 inhibitors like roflumilast. Vaccination, particularly against influenza and pneumococcal infections, is essential in reducing the risk of respiratory infections that trigger exacerbations. Smoking cessation and participation in pulmonary rehabilitation programs are also critical components of exacerbation prevention. Case studies emphasize the importance of patient education and the development of self-management plans that include early intervention during the initial signs of exacerbations (Reis et al., 2018).

3 Common Challenges and Solutions in COPD Management

3.1 Patient adherence issues and intervention strategies

Adherence to medication is a critical challenge in COPD management. Studies show that nearly 60-70% of COPD patients do not adhere to their prescribed medication regimens, which leads to poor disease outcomes, frequent exacerbations, and higher hospitalization rates. Non-adherence is influenced by several factors, including the complexity of treatment regimens, side effects, and patient-related factors such as cognitive impairment, depression, and anxiety (Jarab and Mukattash, 2019). For example, patients on multi-drug regimens or those using inhalers often struggle with proper technique, leading to suboptimal treatment. Psychological factors also play a role, with studies indicating that patients with anxiety or depression are less likely to adhere to their treatment plan.

Strategies to improve adherence focus on patient education, simplifying dosing schedules, and using tools like reminders or electronic adherence monitors. Recent evidence suggests that behavioral interventions such as motivational interviewing and shared decision-making between patients and healthcare providers can significantly enhance adherence. Personalizing interventions, particularly for patients with complex needs, is essential in improving outcomes. Incorporating healthcare professionals, including pharmacists, into the patient’s care team has also shown promise in supporting adherence through regular follow-ups and patient education on inhaler technique and side effects (George, 2018).

3.2 Classic cases of managing comorbidities in COPD

Managing comorbidities in COPD is crucial, as conditions like cardiovascular disease, diabetes, and depression are common and significantly worsen patient outcomes (Wang, 2024). Cardiovascular diseases, in particular, share common risk factors with COPD, such as smoking and inflammation. Studies indicate that COPD patients with heart disease experience higher mortality rates, frequent exacerbations, and longer hospital stays. Proper management of both COPD and cardiovascular diseases is challenging due to overlapping symptoms, such as dyspnea, which complicate diagnosis and treatment decisions (Roversi et al., 2016). Case studies have shown that careful selection of medications, such as beta-blockers for heart failure, can be safely integrated into COPD treatment, reducing cardiovascular complications without exacerbating lung conditions.

Diabetes is another common comorbidity in COPD patients, requiring careful blood sugar management alongside COPD treatments. Effective management requires a multidisciplinary approach where pulmonologists, cardiologists, and endocrinologists collaborate to optimize treatment plans. Additionally, patients with anxiety or depression require psychological support to manage these mental health conditions, which often hinder their ability to follow treatment regimens effectively. Classic case studies emphasize the importance of personalized care plans and integrated treatment strategies to manage both COPD and its associated comorbidities (Hillas et al., 2015).

3.3 Impact of socioeconomic factors on long-term management

Socioeconomic factors profoundly influence the long-term management of COPD. Patients from lower-income backgrounds often face barriers to care, including limited access to healthcare, high medication costs, and inadequate health insurance coverage. These patients are also more likely to live in environments with poor air quality, further exacerbating their respiratory conditions. Studies show that COPD patients from lower socioeconomic groups tend to have higher rates of hospitalization, frequent exacerbations, and poorer overall health outcomes (Pandolfi et al., 2015). Moreover, limited access to education and resources can lead to poor disease self-management, contributing to a cycle of worsening health and increased healthcare costs.

To mitigate these challenges, healthcare systems must focus on improving access to care for underserved populations. This includes providing affordable medications, expanding access to rehabilitation programs, and utilizing telemedicine to reach patients in remote areas. Additionally, community outreach programs can help educate patients about disease management and lifestyle modifications, such as smoking cessation and the use of home oxygen therapy. Tailored interventions targeting these socioeconomic disparities are essential to improving outcomes in COPD patients. Recent evidence suggests that addressing these factors early in the disease progression can significantly reduce hospitalizations and enhance long-term disease control (Stellefson et al., 2019).

4 Role of Inhalation Therapies in COPD Management

4.1 Effectiveness of long-term inhalation therapy in classic cases

Inhalation therapy is a cornerstone of COPD management, with its long-term effectiveness well-documented in classic cases. Inhalers deliver medication directly to the lungs, ensuring rapid action and fewer systemic side effects compared to oral medications. Long-term use of inhalation therapy, particularly bronchodilators like LABAs and LAMAs, has been shown to reduce symptoms, improve lung function, and decrease the frequency of exacerbations. Studies highlight the importance of consistent use, as irregular adherence can lead to poor disease control and increased hospitalizations. For example, patients who followed inhalation regimens for more than a year demonstrated significant improvements in exercise capacity and overall quality of life (Table 1) (Bonini and Usmani, 2015).

However, the effectiveness of inhalation therapy is heavily dependent on correct inhaler technique. Many studies indicate that improper use of inhalers, such as not exhaling fully before inhaling medication or failing to hold one’s breath after inhalation, can reduce drug delivery efficiency and hinder treatment outcomes (Alhomoud, 2016). Overall, long-term inhalation therapy proves highly effective when administered correctly, providing sustained symptom relief and disease control.

4.2 Innovations in inhalation devices and their clinical impact

Recent innovations in inhalation devices have significantly enhanced COPD management, improving both drug delivery and patient outcomes. Newer devices, such as soft mist inhalers (SMIs) and dry powder inhalers (DPIs), are designed to optimize drug deposition in the lungs, even for patients with severe airflow limitations. SMIs, for example, release a slow-moving aerosol, which increases drug deposition efficiency, making them particularly beneficial for elderly patients or those with poor inspiratory flow (Sorino et al., 2020).

In addition to physical improvements, digital innovations such as smart inhalers, which track usage and monitor inhalation techniques, are now helping patients and healthcare providers better understand treatment adherence patterns. These digital tools allow for real-time feedback, reminding patients when to take their medication and alerting healthcare providers when inhaler technique errors occur. Classic cases show that smart inhalers, when integrated into clinical practice, help reduce the number of exacerbations by encouraging better adherence and correct usage (Bosnic-Anticevich et al., 2023). These innovations hold the potential to revolutionize COPD management, making inhalation therapy more effective and user-friendly.

4.3 Patient education and adherence to inhalation therapies

Adherence to inhalation therapy is critical for the successful management of COPD, yet many patients struggle with using inhalers correctly. Studies show that poor inhaler technique, such as improper breath coordination or insufficient inspiratory force, leads to inadequate medication delivery and reduced therapeutic benefits (Hesso et al., 2016). Patient education is a crucial component in improving both adherence and technique. Educational interventions, such as pharmacist-led training sessions or structured teaching by healthcare professionals, have been shown to significantly improve patients' ability to use their inhalers properly.

Classic cases reveal that patients who received tailored education on inhaler technique experienced fewer exacerbations and reported better symptom control compared to those who did not receive such training. These programs often involve repeated sessions to reinforce proper usage and are most effective when integrated into routine care (Vázquez-González et al., 2023). Patient education, coupled with regular reassessments of inhaler technique, ensures long-term adherence to inhalation therapy, ultimately improving disease outcomes and quality of life.

5 Impact of Lifestyle Changes on COPD Outcomes

5.1 Smoking cessation: classic cases and best practices

Smoking cessation is the single most important lifestyle change for patients with COPD, as smoking is the leading cause of the disease. Long-term smoking cessation has been shown to significantly slow the progression of COPD and improve survival rates. Classic cases illustrate that combining behavioral counseling with pharmacotherapy-such as nicotine replacement therapy, varenicline, or bupropion-can increase the likelihood of successful cessation. Studies show that high-intensity behavioral interventions combined with pharmacotherapy can more than double quit rates compared to usual care (Van Eerd et al., 2016).

For instance, patients who participated in structured cessation programs involving counseling and pharmacotherapy demonstrated higher quit rates, with over 50% of participants successfully quitting smoking long-term (Martínez-González et al., 2018). Even in patients with severe COPD, smoking cessation can reduce exacerbation rates and improve lung function, making it a cornerstone of disease management.

5.2 The role of physical activity and rehabilitation programs in COPD management

Physical activity is critical for managing COPD, as it helps improve lung function, reduces exacerbations, and enhances overall quality of life. Pulmonary rehabilitation programs, which combine exercise training, education, and nutritional support, are especially effective. These programs have been shown to reduce hospitalization rates and improve exercise capacity in COPD patients, regardless of disease severity (Garvey, 2016). Classic cases demonstrate that regular physical activity can slow the decline in lung function and improve symptoms. For example, patients who participated in long-term rehabilitation programs reported better control over symptoms and fewer exacerbations, even in advanced stages of COPD (Ambrosino and Bertella, 2018).

Furthermore, studies indicate that increasing physical activity reduces the risk of comorbidities such as cardiovascular disease, which is common in COPD patients. The addition of community-based physical activity interventions to standard smoking cessation treatments has also shown promise in improving overall outcomes (Vander Weg et al., 2017).

5.3 Nutritional interventions and their effect on COPD prognosis

Nutritional status plays a vital role in the prognosis of COPD, as malnutrition is a common problem among patients, particularly those in the later stages of the disease. Poor nutritional intake can exacerbate COPD symptoms and contribute to weight loss, muscle wasting, and reduced respiratory muscle strength. Studies have shown that nutritional interventions, such as oral nutritional supplements and high-protein diets, can improve patient outcomes by increasing body mass and enhancing lung function (Karabeleski et al., 2020).

Classic case studies reveal that patients with COPD who received targeted nutritional support had lower rates of hospitalization and improved exercise tolerance. Nutritional screening tools like BMI assessments and albumin levels help identify patients at risk of malnutrition, and early intervention can prevent the associated decline in health. Moreover, a balanced diet rich in antioxidants and anti-inflammatory nutrients has been linked to reduced inflammation and better disease outcomes in COPD patients (Guilleminault et al., 2018).

6 Innovations and Future Directions

6.1 Classic cases of novel medications and treatment approaches

Recent innovations in medications for COPD have significantly advanced patient care, particularly in the realm of personalized treatment approaches. Novel therapies, such as phosphodiesterase-4 (PDE-4) inhibitors like roflumilast, have emerged as effective treatments for COPD patients with chronic bronchitis and frequent exacerbations. Studies and case reports demonstrate that these medications, when added to traditional inhaler therapies, effectively reduce exacerbations and improve lung function in severe COPD cases (Cazzola et al., 2020).

Another significant development is the introduction of triple therapy inhalers that combine a long-acting muscarinic antagonist (LAMA), long-acting beta-agonist (LABA), and inhaled corticosteroid (ICS) in one device. These inhalers have shown substantial effectiveness in reducing COPD exacerbations and improving overall lung function, especially in patients with more severe disease. Classic case studies highlight that the personalized use of these novel therapies can lead to significant improvements in quality of life and disease management for COPD patients (Fan et al., 2020).

6.2 Application of digital health and remote monitoring in long-term COPD management

Digital health technologies have revolutionized long-term COPD management by enabling continuous monitoring and proactive care. Remote patient monitoring (RPM) systems, such as digital inhalers, smart spirometers, and mobile health platforms, allow for real-time data collection on inhaler use, oxygen levels, and symptoms. This data enables healthcare providers to detect early signs of exacerbation and adjust treatments promptly, reducing hospitalizations and improving patient outcomes (Jacobs and Criner, 2016).

Additionally, digital inhalers equipped with sensors connected to mobile apps have shown promise in enhancing medication adherence and reducing the frequency of COPD exacerbations (Figure 1) (Chan et al., 2021). Remote monitoring technologies not only facilitate personalized treatment adjustments but also empower patients to manage their symptoms more effectively (Zhou, 2024). Despite the challenges of integrating these technologies into routine clinical practice, including costs and patient education, digital health innovations are paving the way for more efficient, data-driven COPD management.

Figure 1 Schematic showing the components of a digital inhaler platform (Adopted from Chan et al., 2021)

6.3 Future research directions in long-term COPD management

The future of COPD management is poised to be driven by emerging technologies and precision medicine. Research efforts will likely focus on further integrating digital health tools, such as artificial intelligence (AI)-based clinical decision support systems (CDSS), into routine care. These systems can analyze patient data to predict exacerbations and provide tailored treatment recommendations, improving outcomes for COPD patients (Pereira et al., 2023). Additionally, wearable devices and multi-sensor technologies will enable real-time monitoring of lung function, physical activity, and environmental exposure, offering a more comprehensive approach to understanding COPD progression (Goyal et al., 2020).

Another promising avenue is regenerative medicine, including stem cell therapies, which aim to repair damaged lung tissue. Future research will also need to address health disparities in COPD care, ensuring that the benefits of these innovations are accessible to all patients, especially those in underserved communities. Continued clinical trials and longitudinal studies are essential to validating these new approaches and optimizing long-term COPD management.

7 Concluding Remarks

Over the past several decades, COPD management has evolved significantly, focusing on both pharmacological and non-pharmacological interventions. Classic cases of inhaler therapies, particularly combinations like LABA/LAMA/ICS, have shown to reduce exacerbations and improve lung function. Non-pharmacological approaches, including pulmonary rehabilitation, smoking cessation, and nutritional support, also play a critical role in managing symptoms and improving patients' quality of life. However, challenges remain, particularly in patient adherence and optimizing treatments based on individual phenotypes. Long-term management strategies require a patient-centered approach that includes education, continuous monitoring, and regular reassessments to ensure the best possible outcomes.

The analysis of classic cases in COPD management highlights the importance of evidence-based practices and individualized care plans. For example, using structured care bundles and self-management education significantly improves adherence, reduces hospitalizations, and enhances patient outcomes. The integration of digital health tools, such as remote monitoring and smart inhalers, further supports these goals by providing real-time data to adjust treatments. Clinical practice can greatly benefit from these case reviews by adopting tailored interventions, especially for patients with frequent exacerbations and comorbidities. Such personalized strategies lead to better patient engagement, greater adherence to treatment plans, and overall improved outcomes.

Future strategies for improving COPD management will likely focus on the continued integration of digital health technologies, such as AI-driven decision support systems and remote patient monitoring, to offer more personalized care. Additionally, more attention will be given to addressing socioeconomic and behavioral barriers to treatment adherence, particularly in underserved populations. Ongoing research into novel therapies, such as regenerative medicine and targeted biologics, also holds promise for treating severe cases of COPD. Finally, the widespread implementation of self-management programs, combined with regular follow-up and education on inhaler techniques, will be crucial for reducing exacerbations and maintaining long-term disease control.

Acknowledgments

I would like to thank two anonymous peer reviewers for their suggestions on my manuscript.

Conflict of Interest Disclosure

The author affirms that this research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest.

References

Alhomoud F., 2016, The use of inhalation therapy in the management of chronic obstructive pulmonary disease (COPD) in the community: a review of studies, BJPharm, 1(1): 14.

https://doi.org/10.5920/BJPHARM.2016.14

Ambrosino N., and Bertella E., 2018, Lifestyle interventions in prevention and comprehensive management of COPD, Breathe, 14(3): 186-194.

https://doi.org/10.1183/20734735.018618

PMID: 30186516 PMCID: PMC6118879

Bonini M., and Usmani O., 2015, The importance of inhaler devices in the treatment of COPD, COPD Research and Practice, 1(1): 1-9.

https://doi.org/10.1186/S40749-015-0011-0

Bosnic-Anticevich S., Bakerly N., Chrystyn H., Hew M., and van der Palen J., 2023, Advancing digital solutions to overcome longstanding barriers in asthma and COPD management, Patient Preference and Adherence, 17: 259-272.

https://doi.org/10.2147/PPA.S385857

PMID: 36741814 PMCID: PMC9891071

Briganti D., and D'Ovidio F., 2017, Long-term management of patients with end-stage lung diseases, Best Practice & Research Clinical Anaesthesiology, 31(2): 167-178.

https://doi.org/10.1016/j.bpa.2017.07.007

PMID: 29110790

Cagle S.D., Landrum L.S., and Kennedy A.M., 2023, Chronic obstructive pulmonary disease: diagnosis and management, American Family Physician, 107(6): 604-612.

Cazzola M., Cavalli F., Usmani O., and Rogliani P., 2020, Advances in pulmonary drug delivery devices for the treatment of chronic obstructive pulmonary disease, Expert Opinion on Drug Delivery, 17(5): 635-646.

https://doi.org/10.1080/17425247.2020.1739021

PMID: 32130023

Chan A.H.Y., Pleasants R.A., Dhand R., Tilley S.L., Schworer S.L., and Costello R.W., 2021, Digital inhalers for asthma or chronic obstructive pulmonary disease: a scientific perspective, Pulmonary Therapy, 7(2): 345-376.

https://doi.org/10.1007/s41030-021-00167-4

PMID: 34379316 PMCID: PMC8589868

Darbà J., Ramírez G., Sicras A., Francoli P., Torvinen S., and Sánchez-de la Rosa R., 2015, The importance of inhaler devices: the choice of inhaler device may lead to suboptimal adherence in COPD patients, International Journal of Chronic Obstructive Pulmonary Disease, 10: 2335-2345.

https://doi.org/10.2147/COPD.S90155

PMID: 26604733 PMCID: PMC4631413

Fan K., Mandel J., Agnihotri P., and Tai-Seale M., 2020, Remote patient monitoring technologies for predicting chronic obstructive pulmonary disease exacerbations: review and comparison, JMIR mHealth and uHealth, 8(5): e16147.

https://doi.org/10.2196/16147

PMID: 32348262 PMCID: PMC7273236

Garvey C., 2016, Recent updates in chronic obstructive pulmonary disease, Postgraduate Medicine, 128(3): 231-238.

https://doi.org/10.1080/00325481.2016.1118352

George M., 2018, Adherence in asthma and COPD: new strategies for an old problem, Respiratory Care, 63: 818-831.

https://doi.org/10.4187/respcare.05905

Goyal P., Calvo F., Maboudian M., Lyu T., Rinderknecht M., and Holzhauer B., 2020, Clinical feasibility study utilizing multi-sensor devices with the goal of developing remote monitoring digital health solutions for patients with asthma or COPD, European Respiratory Journal, 56(64): 1358.

https://doi.org/10.1183/13993003.congress-2020.1358

Güell M., Cejudo P., Ortega F.B., Puy C., Rodríguez-Trigo G., Pijoan J., Martínez-Indart L., Gorostiza A., Bdeir K., Celli B., and Galdiz J., 2017, Benefits of long-term pulmonary rehabilitation maintenance program in patients with severe chronic obstructive pulmonary disease: three-year follow-up, American Journal of Respiratory and Critical Care Medicine, 195: 622-629.

https://doi.org/10.1164/rccm.201603-0602OC

PMID: 27611807

Guilleminault L., Rolland Y., and Didier A., 2018, Characteristics of non-pharmacological interventions in the elderly with COPD: Smoking cessation, pulmonary rehabilitation, nutritional management and patient education, Revue des Maladies Respiratoires, 35(6): 626-641.

https://doi.org/10.1016/j.rmr.2017.12.004

PMID: 29937313

Harrison E., and Kim V., 2019, Long-acting maintenance pharmacotherapy in chronic obstructive pulmonary disease, Respiratory Medicine, (1): 100009

https://doi.org/10.1016/j.yrmex.2019.100009

Hesso I., Gebara S.N., and Kayyali R., 2016, Impact of community pharmacists in COPD management: Inhalation technique and medication adherence, Respiratory Medicine, 118: 22-30.

https://doi.org/10.1016/j.rmed.2016.07.010

PMID: 27578467

Hillas G., Perlikos F., Tsiligianni I., and Tzanakis N., 2015, Managing comorbidities in COPD, International Journal of Chronic Obstructive Pulmonary Disease, 10: 95-109.

https://doi.org/10.2147/COPD.S54473

PMID: 25609943 PMCID: PMC4293292

Jacobs M., and Criner G., 2016, Could digital health applications improve the health of COPD patients?, Expert Review of Respiratory Medicine, 10(4): 377-378.

https://doi.org/10.1586/17476348.2016.1157476

PMID: 26901449

Jarab A., and Mukattash T., 2019, Exploring variables associated with medication non-adherence in patients with COPD, International Journal of Clinical Pharmacy, 41: 1202-1209.

https://doi.org/10.1007/s11096-019-00895-3

PMID: 31468254

Karabeleski E., Petrushevska-Tozi L., Janeku B., Atanasovikj S., Boshkoska D., Andreska M., Mladenovska D., Ivanovska T.P., Nestorovska A.K., and Mladenovska K., 2020, Nutrition in COPD patients - case study, Macedonian Pharmaceutical Bulletin, 66(3): 35-36.

https://doi.org/10.33320/maced.pharm.bull.2020.66.03.017

Martínez-González C., Casanova C., and de-Torres J., 2018, Changes and clinical consequences of smoking cessation in patients with COPD: a prospective analysis from the CHAIN cohort, Chest, 154(2): 274-285.

https://doi.org/10.1016/j.chest.2018.02.007

Pandolfi P., Zanasi A., Musti M., Stivanello E., Pisani L., Angelini S., Maffei F., Hrelia S., Angeloni C., Zenesini C., and Hrelia P., 2015, Socio-economic and clinical factors as predictors of disease evolution and acute events in COPD patients, PLoS ONE, 10(8): e0135116.

https://doi.org/10.1371/journal.pone.0135116

PMID: 26252571 PMCID: PMC4529271

Pereira J., Antunes N., Rosa J., Ferreira J.C., Mogo S., and Pereira M., 2023, Intelligent clinical decision support system for managing COPD patients, Journal of Personalized Medicine, 13(9): 1359.

https://doi.org/10.3390/jpm13091359

PMID: 37763127 PMCID: PMC10532899

Roversi S., Fabbri L., Sin D., Hawkins N., and Agustí A., 2016, Chronic obstructive pulmonary disease and cardiac diseases, American Journal of Respiratory and Critical Care Medicine, 194(11): 1319-1336.

https://doi.org/10.1164/RCCM.201604-0690SO

PMID: 27589227

Sorino C., Negri S., Spanevello A., Visca D., and Scichilone N., 2020, Inhalation therapy devices for the treatment of obstructive lung diseases: the history of inhalers towards the ideal inhaler, European Journal of Internal Medicine, 75: 15-18.

https://doi.org/10.1016/j.ejim.2020.02.023

PMID: 32113944

Stellefson M., Paige S.R., Barry A., Wang M., and Apperson A., 2019, Risk factors associated with physical and mental distress in people who report a COPD diagnosis, International Journal of Chronic Obstructive Pulmonary Disease, 14: 809-822.

https://doi.org/10.2147/COPD.S194018

PMID: 31040659 PMCID: PMC6462160

Van Eerd E.A.V., van der Meer R.M., van Schayck O.V., and Kotz D., 2016, Smoking cessation for people with chronic obstructive pulmonary disease, Cochrane Database of Systematic Reviews, (8): CD010744.

https://doi.org/10.1002/14651858.CD010744.pub2

PMID: 27545342 PMCID: PMC6400424

Vander Weg M.V., Coday M., and Stockton M., 2017, Community-based physical activity as adjunctive smoking cessation treatment: rationale, design, and baseline data for the lifestyle enhancement program (LEAP) randomized controlled trial, Contemporary Clinical Trials Communications, 9: 50-59.

https://doi.org/10.1016/j.conctc.2017.11.013

PMID: 29333504 PMCID: PMC5760189

Vázquez-González N., Leiva-Fernández J., Cotta-Luque V., Leiva-Fernández F., and Rius-Díaz F., 2023, Effectiveness of an educational intervention about inhalation technique in healthcare professionals in primary care: a cluster randomized trial, Frontiers in Pharmacology, 14.

https://doi.org/10.3389/fphar.2023.1266095

PMID: 37915412 PMCID: PMC10617029

Wang W., 2024, The role of genomics in the prevention of cardiovascular diseases, International Journal of Molecular Medical Science, 14(1): 69-79.

https://doi.org/10.5376/ijmms.2024.14.0010

Zhou J.Y., 2024, The application of genomics in personalized cancer therapy, Cancer Genetics and Epigenetics, 12(1): 66-74.

https://doi.org/10.5376/cge.2024.12.0009